These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 23473805)
1. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition. Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805 [TBL] [Abstract][Full Text] [Related]
2. Key role of nuclear factor-κB in the cellular pharmacokinetics of adriamycin in MCF-7/Adr cells: the potential mechanism for synergy with 20(S)-ginsenoside Rh2. Zhang J; Lu M; Zhou F; Sun H; Hao G; Wu X; Wang G Drug Metab Dispos; 2012 Oct; 40(10):1900-8. PubMed ID: 22745335 [TBL] [Abstract][Full Text] [Related]
3. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145 [TBL] [Abstract][Full Text] [Related]
4. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169 [TBL] [Abstract][Full Text] [Related]
5. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells. George JA; Chen T; Taylor CC Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028 [TBL] [Abstract][Full Text] [Related]
6. A novel indirubin derivative PHII-7 potentiates adriamycin cytotoxicity via inhibiting P-glycoprotein expression in human breast cancer MCF-7/ADR cells. Shi R; Li W; Zhang X; Zhang Y; Peng H; Xie Y; Fan D; Liu R; Liu X; Xiong D Eur J Pharmacol; 2011 Nov; 669(1-3):38-44. PubMed ID: 21871878 [TBL] [Abstract][Full Text] [Related]
7. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318. Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation. Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858 [TBL] [Abstract][Full Text] [Related]
9. CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function. Tang SJ; Chen LK; Wang F; Zhang YK; Huang ZC; To KK; Wang XK; Talele TT; Chen ZS; Chen WQ; Fu LW Biochem Pharmacol; 2014 Sep; 91(2):144-56. PubMed ID: 25058526 [TBL] [Abstract][Full Text] [Related]
10. Reversal effects of two new milbemycin compounds on multidrug resistance in MCF-7/adr cells in vitro. Gao A; Liang H; Wang X; Zhang X; Jing M; Zhang J; Yan Y; Xiang W Eur J Pharmacol; 2011 Jun; 659(2-3):108-13. PubMed ID: 21458446 [TBL] [Abstract][Full Text] [Related]
11. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol. Arora A; Seth K; Kalra N; Shukla Y Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829 [TBL] [Abstract][Full Text] [Related]
12. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280 [TBL] [Abstract][Full Text] [Related]
13. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR. Shen J; Wang Q; Hu Q; Li Y; Tang G; Chu PK Biomaterials; 2014 Oct; 35(30):8621-34. PubMed ID: 25002258 [TBL] [Abstract][Full Text] [Related]
14. Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistance. Chen G; Waxman DJ J Pharmacol Exp Ther; 1995 Sep; 274(3):1271-7. PubMed ID: 7562498 [TBL] [Abstract][Full Text] [Related]
15. Drug resistance in chemotherapy for breast cancer. Saeki T; Tsuruo T; Sato W; Nishikawsa K Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():84-9. PubMed ID: 16273361 [TBL] [Abstract][Full Text] [Related]
16. Down-regulation of P-glycoprotein expression in MDR breast cancer cell MCF-7/ADR by honokiol. Xu D; Lu Q; Hu X Cancer Lett; 2006 Nov; 243(2):274-80. PubMed ID: 16406853 [TBL] [Abstract][Full Text] [Related]
17. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. Ji BS; He L J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197 [TBL] [Abstract][Full Text] [Related]
18. Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells. Yu ST; Chen TM; Tseng SY; Chen YH Biochem Biophys Res Commun; 2007 Jun; 358(1):79-84. PubMed ID: 17482571 [TBL] [Abstract][Full Text] [Related]
19. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
20. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin. Li H; Krstin S; Wink M Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]